Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jie Chen

Physician Assistant Quincy, MA Physician Assistant

NPI 1336410398 CMS profile 10496781

500 Congress St Ste B1, Quincy, MA 02169

Open in the dashboard

General payments

$21,562

1,054 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jie Chen of Quincy, MA is reported in the CMS Open Payments database as having received $21,562 across 1,054 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,175 329
2024 General $5,849 300
2023 General $5,903 233
2022 General $2,080 112
2021 General $1,556 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jie Chen
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jie Chen were reported at $6,175. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jie Chen Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,556 $132 $37–$438 $132
2022 $2,080 $155 $48–$522 $149
2023 $5,903 $167 $52–$557 $160
2024 $5,849 $178 $55–$600 $164
2025 $6,175 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,562 108 payments
  2. AbbVie, Inc. $2,000 116 payments
  3. Mayne Pharma Inc. $1,991 15 payments
  4. Sun Pharmaceutical Industries Inc. $1,954 108 payments
  5. Novartis Pharmaceuticals Corporation $1,899 127 payments
  6. Arcutis Biotherapeutics, Inc. $1,619 34 payments
  7. E.R. Squibb & Sons, L.L.C. $1,260 83 payments
  8. UCB, Inc. $1,160 89 payments
  9. Biofrontera Inc. $1,070 55 payments
  10. Dermavant Sciences, Inc. $1,064 60 payments
  11. Other $4,982 259 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $19,078 1,043 payments
  2. Consulting Fee $1,800 2 payments
  3. Education $684 9 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,466 103 payments
  2. Zoryve $1,548 30 payments
  3. ILUMYA $1,360 71 payments
  4. VTAMA $1,172 67 payments
  5. SOTYKTU $1,171 76 payments
  6. COSENTYX $1,100 79 payments
  7. SKYRIZI $963 53 payments
  8. Bimzelx $834 63 payments
  9. BF-RhodoLED $781 40 payments
  10. XEPI $781 40 payments
  11. Other $11,794 685 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,544

Median for Physician Assistant: 241

Drug cost

$223,360

Median for Physician Assistant: $4,110

Branded share of claims

4.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tavaborole Generic 72 $91,456
Crotan Crotamiton Brand 36 $44,411
Adapalene Generic 13 $33,655
Oxiconazole Nitrate Generic 33 $14,972
Betamethasone Dipropionate Generic 135 $9,079
Ammonium Lactate Generic 245 $5,349
Triamcinolone Acetonide Generic 119 $4,172
Ketoconazole Generic 156 $3,358
Fluocinonide Generic 51 $2,231
Clindamycin Phosphate Generic 27 $2,170

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$174,219

Of which drugs: $7,388

Medicare patients

512

Average age 72

Services billed

3,416

351 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 47%
Diabetes 31%
Ischemic heart disease 28%
Osteoporosis 23%
Depression 19%
Chronic kidney disease 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 12 23 $7,122
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 13 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
$884 — —
VTAMA
$643 — —
TREMFYA
$564 — —
SOTYKTU
$520 — —
COSENTYX
$439 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,054 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record